ChemoCentryx, Inc. (CCXI) Q3 2020 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the Chemocentrics Third Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. As a reminder, this conference call will be recorded. I would now like to turn it over to Steve Klass of Burns McLaren. Mr. Klass, please go ahead. Thank you, Operator. Good afternoon and welcome to the Chemocentrics third quarter 2020 financial results conference call. Earlier this afternoon, the company issued a press release providing an overview of its financial results for the third quarter ended September 30th, 2020. This press release is available on the investor relations section of the company's website at www.chemocentrics.com. Please note there is a slide deck to accompany this call, which can also be found on the company's website. Joining me on the call today is Dr. Thomas Shaw, President and Chief Executive Officer of ChemoCentrics, who will review the company's recent business and clinical progress. Following his comments, Susan Kanaya, Executive Vice President, Chief Financial and Administrative Officer, will provide an overview of the company's financial highlights for the third quarter before turning the call back over to Tom for closing remarks. During today's call, we will be making certain forward-looking statements. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These risks are described in the company's filings made with the Securities and Exchange Commission, including the company's annual report on Form ...